Product Information
COSENTYX SENSOREADY 300 MG DOSE/2 PENS (150 MG/PEN) is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $3946.3486 per ML under NDC 00078063941. Its NADAC has been published 481 times since Jul 19, 2017.
Strength
150 mg/mL
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078063941
Classification
Brand
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
SECUKINUMABApproval Type
Biologic (BLA)
FDA Application
BLA125504On Market Since
1/21/2015
Pharmacological Classes
Price Statistics
The NADAC for COSENTYX SENSOREADY 300 MG DOSE/2 PENS (150 MG/PEN) has been published 481 times since Jul 19, 2017, and over the history we have for it it has risen 87.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3946.3486 per ML |
|---|---|
| All-time high | $3976.8992 (Jun 10, 2026) |
| All-time low | $2106.4112 (Jul 19, 2017) |
| 52-week high | $3976.8992 |
| 52-week low | $3691.2023 |
| Median price | $3045.4215 |
| Average price | $3031.0412 |
| Largest weekly change | +9.9% (Jan 23, 2019) |
| Weeks tracked | 481 |
| Tracking since | Jul 19, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novartis Pharmaceuticals Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
secukinumab market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Interleukin-17A Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of COSENTYX SENSOREADY 300 MG DOSE/2 PENS (150 MG/PEN)?
The current National Average Drug Acquisition Cost (NADAC) for COSENTYX SENSOREADY 300 MG DOSE/2 PENS (150 MG/PEN), manufactured by Novartis Pharmaceuticals Corporation, is $3946.3486 per ML (NDC 00078063941), effective Sep 30, 2026.
How has the price of COSENTYX SENSOREADY 300 MG DOSE/2 PENS (150 MG/PEN) changed over time?
Over the history we have for it, the NADAC for COSENTYX SENSOREADY 300 MG DOSE/2 PENS (150 MG/PEN) has risen 87.3%. It has been tracked across 481 weekly CMS publications since Jul 19, 2017.
What are the highest and lowest recorded NADAC prices for COSENTYX SENSOREADY 300 MG DOSE/2 PENS (150 MG/PEN)?
Since Jul 19, 2017, the NADAC for COSENTYX SENSOREADY 300 MG DOSE/2 PENS (150 MG/PEN) has ranged from a low of $2106.4112 (Jul 19, 2017) to a high of $3976.8992 (Jun 10, 2026), with a median of $3045.4215 per ML.
Are there cheaper alternatives to COSENTYX SENSOREADY 300 MG DOSE/2 PENS (150 MG/PEN)?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, COSENTYX (150 MG/ML) 300 MG DOSE-2 SYRINGES, is $3924.3531 per ML — about 1% below COSENTYX SENSOREADY 300 MG DOSE/2 PENS (150 MG/PEN).
Who manufactures COSENTYX SENSOREADY 300 MG DOSE/2 PENS (150 MG/PEN)?
COSENTYX SENSOREADY 300 MG DOSE/2 PENS (150 MG/PEN) (NDC 00078063941) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.